Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models
Open Access
- 23 December 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (12) , 10457-10469
Abstract
Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer modelsKeywords
This publication has 40 references indexed in Scilit:
- RETRACTED ARTICLE: Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathwayScientific Reports, 2016
- MIA PaCa-2 and PANC-1 – pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptorsScientific Reports, 2016
- Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivoTumor Biology, 2016
- Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressorInternational Journal of Oncology, 2016
- HTSeq—a Python framework to work with high-throughput sequencing dataBioinformatics, 2014
- Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.2011
- A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing dataBioinformatics, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of Clinical Oncology, 2002